POEMS (Polyneuropathy, Organomegaly, Endocrinopathies, Monoclonal protein, Skin
changes) syndrome is a rare paraneoplastic syndrome related to plasma cell disorders. The …

Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell
transplantation (ASCT) has established itself as a core treatment for newly diagnosed …

Background The financial impact of cancer medicines on health systems is not well known.
We describe temporal trends in expenditure on cancer medicines within the single-payer …

Background The primary analysis of the APOLLO trial, done after a median follow-up of 16· 9
months, showed that daratumumab plus pomalidomide and dexamethasone significantly …

High-risk multiple myeloma (MM) is often defined based on cytogenetic abnormalities, but
patients who relapse early after initial therapy are considered a functional high-risk group. In …

Objectives The current study aims to evaluate the safety and efficacy of anti-CD38
monoclonal antibodies (mAbs) among patients with relapsed/refractory multiple myeloma …

The treatment of multiple myeloma has evolved significantly over the past few decades with
the development of novel therapeutics. The introduction of proteasome inhibitors …

Introduction Systemic AL amyloidosis, a plasma cell dyscrasia, is characterized by the
production of misfolded immunoglobulin light chain. These misfolded proteins aggregate …

Multiple Myeloma (MM) is a plasma cell cancer with high mortality and morbidity rates. Its
incidence rate has increased by 143% since 1975. Adipokines, cytokines, chemokines, and …

The incorporation of immunomodulatory drugs (IMiDs; lenalidomide and pomalidomide) and
proteasome inhibitors (bortezomib, ixazomib, and carfilzomib) in the treatment of multiple …